Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update
by Teresa Graham · The Cerbat GemAlpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 771,223 shares, a growth of 34.4% from the March 15th total of 573,837 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 212,421 shares, the days-to-cover ratio is presently 3.6 days.
Institutional Trading of Alpha Tau Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mariner LLC increased its holdings in shares of Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after buying an additional 1,915 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new stake in shares of Alpha Tau Medical during the 4th quarter worth approximately $48,000. Levin Capital Strategies L.P. increased its holdings in shares of Alpha Tau Medical by 6.3% during the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after buying an additional 12,200 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after buying an additional 17,500 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.
Alpha Tau Medical Price Performance
Shares of DRTS stock traded up $0.05 during trading hours on Wednesday, reaching $7.88. The company had a trading volume of 267,022 shares, compared to its average volume of 341,721. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The stock has a fifty day moving average of $7.22 and a 200-day moving average of $5.70. The company has a market capitalization of $668.38 million, a price-to-earnings ratio of -14.87 and a beta of 1.04. Alpha Tau Medical has a 12-month low of $2.50 and a 12-month high of $8.60.
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, equities analysts anticipate that Alpha Tau Medical will post -0.45 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on DRTS shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Piper Sandler reiterated a “neutral” rating and issued a $5.00 price objective on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Citigroup boosted their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.67.
View Our Latest Analysis on DRTS
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.